| 1 |
Aghamiri SS, Puniya BL, Amin R, Helikar T. A multiscale mechanistic model of human dendritic cells for in-silico investigation of immune responses and novel therapeutics discovery. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1112985] [Reference Citation Analysis]
|
| 2 |
Gao X, Zuo S. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells. Clin Exp Med 2023. [PMID: 36773210 DOI: 10.1007/s10238-023-01015-2] [Reference Citation Analysis]
|
| 3 |
Jahani V, Yazdani M, Badiee A, Jaafari MR, Arabi L. Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma. J Control Release 2023;354:453-64. [PMID: 36649743 DOI: 10.1016/j.jconrel.2023.01.034] [Reference Citation Analysis]
|
| 4 |
Pozharov VP, Minko T. Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges. Pharmaceutics 2023;15. [PMID: 36678823 DOI: 10.3390/pharmaceutics15010194] [Reference Citation Analysis]
|
| 5 |
Chan L, Wood GA, Wootton SK, Bridle BW, Karimi K. Neutrophils in Dendritic Cell-Based Cancer Vaccination: The Potential Roles of Neutrophil Extracellular Trap Formation. Int J Mol Sci 2023;24. [PMID: 36674412 DOI: 10.3390/ijms24020896] [Reference Citation Analysis]
|
| 6 |
Zhang R, Neighbors J, Schell T, Hohl R. Schweinfurthin induces ICD without ER stress and caspase activation. OncoImmunology 2022;11:2104551. [DOI: 10.1080/2162402x.2022.2104551] [Reference Citation Analysis]
|
| 7 |
Rackl E, Li L, Klauer LK, Ugur S, Pepeldjiyska E, Seidel CL, Gunsilius C, Weinmann M, Doraneh-Gard F, Reiter N, Plett C, Amberger DC, Bojko P, Kraemer D, Schmohl J, Rank A, Schmid C, Schmetzer HM. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes. Int J Mol Sci 2022;24. [PMID: 36613907 DOI: 10.3390/ijms24010463] [Reference Citation Analysis]
|
| 8 |
Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol 2022;13:1029069. [PMID: 36591226 DOI: 10.3389/fimmu.2022.1029069] [Reference Citation Analysis]
|
| 9 |
Zhou J, Li L, Jia M, Liao Q, Peng G, Luo G, Zhou Y. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions. Cancer Medicine 2022. [DOI: 10.1002/cam4.5511] [Reference Citation Analysis]
|
| 10 |
Niemi JVL, Sokolov AV, Schiöth HB. Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments. Cancers (Basel) 2022;14:5163. [PMID: 36291947 DOI: 10.3390/cancers14205163] [Reference Citation Analysis]
|
| 11 |
Schakelaar MY, Monnikhof M, Crnko S, Pijnappel E, Meeldijk J, Ten Broeke T, Bovenschen N. Cellular Immunotherapy for Medulloblastoma. Neuro Oncol 2022:noac236. [PMID: 36219688 DOI: 10.1093/neuonc/noac236] [Reference Citation Analysis]
|
| 12 |
Bunse L, Bunse T, Krämer C, Chih YC, Platten M. Clinical and Translational Advances in Glioma Immunotherapy. Neurotherapeutics 2022;19:1799-817. [PMID: 36303101 DOI: 10.1007/s13311-022-01313-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Kalkusova K, Smite S, Darras E, Taborska P, Stakheev D, Vannucci L, Bartunkova J, Smrz D. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors. IJMS 2022;23:11080. [DOI: 10.3390/ijms231911080] [Reference Citation Analysis]
|
| 14 |
Tsao SY. Potential of mRNA vaccines to become versatile cancer vaccines . World J Clin Oncol 2022; 13(8): 663-674 [DOI: 10.5306/wjco.v13.i8.663] [Reference Citation Analysis]
|
| 15 |
Asija S, Chatterjee A, Yadav S, Chekuri G, Karulkar A, Jaiswal AK, Goda JS, Purwar R. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Int Rev Immunol 2022;:1-24. [PMID: 35938932 DOI: 10.1080/08830185.2022.2101647] [Reference Citation Analysis]
|
| 16 |
Kim H, Shin SJ. Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion. Front Cell Infect Microbiol 2022;12:891878. [DOI: 10.3389/fcimb.2022.891878] [Reference Citation Analysis]
|
| 17 |
Argenziano M, Occhipinti S, Scomparin A, Angelini C, Novelli F, Soster M, Giovarelli M, Cavalli R. Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting. Drug Deliv and Transl Res . [DOI: 10.1007/s13346-022-01185-8] [Reference Citation Analysis]
|
| 18 |
Du Z, Huang Z, Chen X, Jiang G, Peng Y, Feng W, Huang N. Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation. Exp Hematol Oncol 2022;11:36. [PMID: 35672796 DOI: 10.1186/s40164-022-00289-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 19 |
Rothe F, Patties I, Kortmann RD, Glasow A. Immunomodulatory Effects by Photodynamic Treatment of Glioblastoma Cells In Vitro. Molecules 2022;27:3384. [PMID: 35684322 DOI: 10.3390/molecules27113384] [Reference Citation Analysis]
|
| 20 |
Kolostova K, Pospisilova E, Matkowski R, Szelachowska J, Bobek V. Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells. Cancer Immunol Immunother 2022. [PMID: 35471603 DOI: 10.1007/s00262-022-03189-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Crivii CB, Boșca AB, Melincovici CS, Constantin AM, Mărginean M, Dronca E, Suflețel R, Gonciar D, Bungărdean M, Șovrea A. Glioblastoma Microenvironment and Cellular Interactions. Cancers (Basel) 2022;14:1092. [PMID: 35205842 DOI: 10.3390/cancers14041092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
